ReviewInternational journal of molecular sciences2026
Inflammation and Diabetic Kidney Disease.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- HALP score and risk of renal progression in diabetic kidney disease.Acta diabetologica · 2026Article
- Hemodynamic effects of finerenone on blood pressure and heart rate in hospitalized patients with type 2 diabetes: a real-world study.Frontiers in endocrinology · 2026Observational
- Unveiling the immune microenvironment in diabetic nephropathy: from mechanisms to therapeutics.Frontiers in immunology · 2026Review
- White Blood Cell-to-Hemoglobin Ratio, a Promising Indicator for Diabetic Kidney Disease: An Observational Cross-Sectional Study.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Diabetes is the leading cause of end-stage kidney disease and significantly contributes to morbidity and mortality in people with diabetes. Despite significant advances in the last decade, including the development of novel therapies, the residual risk in diabetic kidney disease (DKD) remains high. One yet unaddressed factor in the pathogenesis of DKD is immune activation. Early in DKD, there is infiltration of macrophages, T-cells, B-cells, and dendritic cells in mouse models, while at later stages, neutrophils are also observed. This review will highlight novel insights into the contribution of immune cells to the development of DKD, with a particular focus on the innate immune system and the cellular crosstalk between immune cells and intrinsic kidney cells as contributors to DKD. One example of this bidirectional crosstalk is observed between macrophages and podocytes. While macrophages can directly mediate podocyte injury and apoptosis via TNF-α secretion, podocytes secrete cytokines that further recruit macrophages. Understanding the role of immune-mediated injury in kidney disease is critical in reducing the residual risk of DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.